Anfield Capital Management, LLC
Position in HRTX — Heron Therapeutics, Inc. /De/
CIK 1602020
IRVINE, CA
Position in HRTX
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$24,000
-$15,000 QoQ
Shares Held
30,000
0.0% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HRTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Anfield Capital Management, LLC holds $4,283,063 across 7 Biotechnology names. HRTX ranks #4 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
119,451 | $3,308,792 | |
| 2 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
274,516 | $642,367 | |
| 3 | IMNM |
Immunome Inc.
|
13,647 | $298,459 | |
| 4 | HRTX |
Heron Therapeutics, Inc. /De/
This page
|
30,000 | $24,000 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
100 | $7,426 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3 | $1,339 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
36 | $680 |
All Filings in HRTX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $24,000 | 30,000 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $39,000 | 30,000 | Shares | Defined | 2026-02-03 | |
| 2025-09-30 | $37,800 | 30,000 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $62,100 | 30,000 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $310,607 | 141,185 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $182,033 | 118,976 | Shares | Defined | 2025-02-05 | |
| 2024-09-30 | $224,296 | 112,712 | Shares | Defined | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||